Table 2 Evolving evidence on incidence of Pfizer vaccine-associated myocarditis by age and sex in Australia in October–December 2021.
Date | Sex | Age 12–19 years | Age 20–29 years | Age 30–39 years | Age 40–49 years | Age 50–59 years | Age 60–69 years | Age ≥70 years | |
|---|---|---|---|---|---|---|---|---|---|
Estimated incidence of myocarditis per million 2nd dosesa | 14/10/21 | Male | 75 | 22 | 6 | 10 | 3 | 0 | 0 |
Female | 14 | 12 | 3 | 10 | 3 | 0 | 0 | ||
9/12/21 | Male | 103 | 59 | 15 | 11 | 1 | 0 | 0 | |
Female | 25 | 19 | 6 | 9 | 4 | 0 | 0 | ||
Estimated deaths per million 2nd doses based on 0.34% CFRb | 14/10/21 | Male | 0.128 | 0.037 | 0.01 | 0.017 | 0.005 | 0 | 0 |
Female | 0.024 | 0.02 | 0.005 | 0.017 | 0.005 | 0 | 0 | ||
9/12/21 | Male | 0.175 | 0.1 | 0.026 | 0.019 | 0.002 | 0 | 0 | |
Female | 0.043 | 0.032 | 0.01 | 0.015 | 0.007 | 0 | 0 | ||
Difference in estimated cases per million 2nd doses compared to 14/10/21 | 9/12/21 | Male | 28 | 37 | 9 | 1 | 2 | 0 | 0 |
Female | 11 | 7 | 3 | 1 | 1 | 0 | 0 | ||
Difference in estimated deaths per million 2nd doses compared to 14/10/21 | 9/12/21 | Male | 0.048 | 0.063 | 0.015 | 0.002 | 0.003 | 0 | 0 |
Female | 0.019 | 0.012 | 0.005 | 0.002 | 0.002 | 0 | 0 |
